Millipore Sigma Vibrant Logo

07-1372 Anti-PTEN Antibody

07-1372
100 µg  
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, R, CaWB, IFRbAffinity PurifiedPolyclonal Antibody
      Description
      Catalogue Number07-1372
      Replaces04-409
      DescriptionAnti-PTEN Antibody
      Alternate Names
      • MMAC1 phosphatase and tensin homolog deleted on chromosome 10
      • Mutated in multiple advanced cancers 1
      • phosphatase and tensin homolog
      • phosphatase and tensin homolog (mutated in multiple advanced cancers
      Background InformationThe protein and lipid phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome ten) has been suggested to play a role in tumorgenesis. PTEN is a tumor suppressor whose loss permits constitutive signaling through the PI3K pathway and is sufficient to cause cancer. In normal cells, in conjunction with FOXO1A and PTEN function together to restrain cell growth. PTEN metabolizes the product of PI3K phosphorylation of PI(4,5)P2 following receptor activation, creating PI(3,4,5)P3. In cells lacking PTEN, there are elevated levels of PI(3,4,5)P3, which acts as a potent second messenger promoting oncogenesis. Restoration of PTEN function is considered a novel approach to cancer therapy. Overexpression of PTEN inhibits cell migration, and expression of antisense PTEN mRNA enhances migration.
      Product Information
      FormatAffinity Purified
      PresentationPurified rabbit polyclonal in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with with 0.05% sodium azide.
      Quality LevelMQ100
      Applications
      ApplicationDetect PTEN using this Anti-PTEN Antibody validated for use in WB & IF.
      Key Applications
      • Western Blotting
      • Immunofluorescence
      Biological Information
      ImmunogenGST fusion protein corresponding to amino acids 239-403 of human PTEN.
      EpitopeC-terminus
      HostRabbit
      SpecificityDetects PTEN
      Species Reactivity
      • Human
      • Mouse
      • Rat
      • Canine
      Species Reactivity NoteHuman, Mouse, and Rat. Other species have not been tested. Canine expected to react based on complete sequence homology.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. [provided by RefSeq]
      Gene Symbol
      • BZS
      • EC 3.1.3.67
      • EC 3.1.3.16
      • EC 3.1.3.48
      • MGC11227
      • MHAM
      • MMAC1
      • PTEN1
      • TEP1
      Purification MethodImmunogen Affinity Purified and anti-GST depleted.
      UniProt Number
      UniProt SummaryFunction: Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. Ref.1 Ref.10 Ref.11 Ref.12 Ref.13 Ref.14 Ref.18
      Catalytic activity: Phosphatidylinositol 3,4,5-trisphosphate + H(2)O = phosphatidylinositol 4,5-bisphosphate + phosphate. Ref.1 Ref.10 Ref.11 Ref.12
      A phosphoprotein + H(2)O = a protein + phosphate. Ref.1 Ref.10 Ref.11 Ref.12
      Protein tyrosine phosphate + H(2)O = protein tyrosine + phosphate. Ref.1 Ref.10 Ref.11 Ref.12
      Cofactor: Magnesium.
      Subunit structure: Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro. Interacts with MAGI3. Ref.18 Ref.15 Ref.16 Ref.17 Ref.20
      Subcellular location: Cytoplasm. Ref.1
      Tissue specificity: Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas. Ref.2
      Induction Down-regulated by transforming growth factor beta (TGF-beta). Ref.1
      Domain: The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function. Ref.14 Ref.20
      Post-translational modification: Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit and promote PDZ-binding.
      Involvement in disease: Mutations of PTEN are found in a large number of cancers. Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD.
      Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes.
      Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Riley-Smith or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis.
      Defects in PTEN are implicated in a number of diseases.
      Sequence similarities: Contains 1 C2 tensin-type domain.


      Molecular Weight55 kDa
      Product Usage Statements
      Quality AssuranceWestern Blot Analysis:
      This lot detected PTEN at 1:1,000 dilution in HEK293 cell lysate resolved via SDS-PAGE and transferred to PVDF.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
      Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
      Packaging Information
      Material Size100 µg
      Global Trade Item Number
      Catalogue Number GTIN
      07-1372 04053252283901